Blossomhill Therapeutics, Inc. <BLSM.O>: H.C. Wainwright initiates coverage with buy rating and target price $35
BLSM•Related News
Designer Brands Inc. <DBI.N>: UBS cuts target price to $6 from $7.5
DBI•
Daxor wins US patent for remote blood volume monitoring technology
DXR•
Perma-Pipe, Welspun sign MOU to form Jordan pipe manufacturing and coating JV
PPIH•
Vera Bradley sets fiscal Q2 earnings release, conference call
VRA•
Iron Horse Acquisition II, ELECTRA AI join Mooving to power battery analytics for India swapping network
IRHO•